8:20 am Chair’s Opening Remarks: The Value Proposition of Early Identification & Intervention of Kidney Disease
SGLT2: What’s Next? Highlighting Challenge & Opportunity for Additional Drug Development
8:45 am Learning from Diabetes & Heart Failure Conversations: Drug Development in Addition to SGLT2 Inhibition as Standard of Care
9:15 am Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case:
9:45 am Speed Networking
10:30 am Morning Break & Networking
Translational Drug Development Track
Chaired By: Jeremy Duffield, Global Head of Human Biology, Vertex Pharmaceuticals
Later Stage Clinical& Commercial Drug Development Track
Chaired By: Uptal Patel, Executive Director, Clinical Research, Gilead
Disease Modeling for More Predictive Translation & Mechanistic Discovery
11.30 Applications of Kidney Organoid Disease Models to Optimize Drug Discovery Opportunity
Beno Freedman, Assistant Professor – Nephrology, University of Washington
12.00 Bioengineering Technologies to Model Renal Systems
Jonathan Himmelfarb, Director of the Kidney Research Institute & Professor of Medicine, University of Washington
Accessing & Interrogating Data to Inform Drug Target Discovery
12.30 Tissue Transcriptomics to Understand Molecular Mechanisms of Progressive CKD & Mechanism-based Patient Stratification
Wenjun Ju, Associate Research Scientist of Internal Medicine, University of Michigan
Enhancing Patient Recruitment & Selection for Clinical Trials in Orphan Indications
11.30 Biomarkers as Key Drug Development Tools
Vishal Vaidya, Translational Omics Group Head, Pfizer
12.00 From Diagnostic to Therapeutic Targets
Tzu-Ling (Karen) Tseng, Chief Executive Officer, Bio Preventive Medicine Corp
12.30 Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems
Dorothee Oberdhan, Associate Director, Health Outcomes, Otsuka Pharmaceuticals
Josh Tarnoff, Chief Executive Officer, NephCure
Uptal Patel, Executive Director, Clinical Research, Gilead